Lindsay's rising ROCE and capital employed are encouraging, indicating successful business reinvestment and higher returns. These promising trends may be underappreciated by investors, potentially making the stock a solid long-term investment.
Lindsay Corporation's in-line P/E ratio omits its weaker earnings forecast. A P/E fall to match growth outlook may upset investors. Balance sheet risks cause unease.
Given Lindsay's rapid earnings growth, its reinvestment of profits into business expansion, along with a conservative payout ratio, the company appears to have strong prospects for future growth and a reduced risk of future dividend cuts.
The positive trends in Lindsay's ROCE and capital employment are encouraging signs for its potential as an investment. The current shareholder return of 34% over the past five years suggests the market may not yet fully recognize Lindsay's promising fundamentals.
Lindsay Stock Forum
• $Cytokinetics (CYTK.US)$ +8.7% (prices offering of of $450.0 mln of 3.50% convertible senior notes due 2027)
• $XPeng (XPEV.US)$ +3.4% (June deliveries)
• $NIO Inc (NIO.US)$ +2.9% (June deliveries)
• $Bitfarms (BITF.US)$ +2.7% (provides June 2022 production and mining operations update)
• $Accolade (ACCD.US)$ +2.7% (In reaction to earnings/guidance)
• $BioCryst Pharmaceuticals (BCRX.US)$ +2.6% (presents new data demonstrating...
No comment yet